Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

728 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Radiofrequency ablation vs endoscopic surveillance for patients with Barrett esophagus and low-grade dysplasia: a randomized clinical trial.
Phoa KN, van Vilsteren FG, Weusten BL, Bisschops R, Schoon EJ, Ragunath K, Fullarton G, Di Pietro M, Ravi N, Visser M, Offerhaus GJ, Seldenrijk CA, Meijer SL, ten Kate FJ, Tijssen JG, Bergman JJ. Phoa KN, et al. Among authors: tijssen jg. JAMA. 2014 Mar 26;311(12):1209-17. doi: 10.1001/jama.2014.2511. JAMA. 2014. PMID: 24668102 Clinical Trial.
The cost-effectiveness of radiofrequency ablation for Barrett's esophagus with low-grade dysplasia: results from a randomized controlled trial (SURF trial).
Phoa KN, Rosmolen WD, Weusten BLAM, Bisschops R, Schoon EJ, Das S, Ragunath K, Fullarton G, DiPietro M, Ravi N, Tijssen JGP, Dijkgraaf MGW, Bergman JJGHM; SURF investigators. Phoa KN, et al. Gastrointest Endosc. 2017 Jul;86(1):120-129.e2. doi: 10.1016/j.gie.2016.12.001. Epub 2016 Dec 9. Gastrointest Endosc. 2017. PMID: 27956164 Clinical Trial.
Patients With Barrett's Esophagus and Confirmed Persistent Low-Grade Dysplasia Are at Increased Risk for Progression to Neoplasia.
Duits LC, van der Wel MJ, Cotton CC, Phoa KN, Ten Kate FJW, Seldenrijk CA, Offerhaus GJA, Visser M, Meijer SL, Mallant-Hent RC, Krishnadath KK, Pouw RE, Tijssen JGP, Shaheen NJ, Bergman JJGHM. Duits LC, et al. Gastroenterology. 2017 Apr;152(5):993-1001.e1. doi: 10.1053/j.gastro.2016.12.008. Epub 2016 Dec 22. Gastroenterology. 2017. PMID: 28012849
Improved diagnostic stratification of digitised Barrett's oesophagus biopsies by p53 immunohistochemical staining.
van der Wel MJ, Duits LC, Pouw RE, Seldenrijk CA, Offerhaus GJA, Visser M, Ten Kate FJ, Biermann K, Brosens LAA, Doukas M, Huysentruyt C, Karrenbeld A, Kats-Ugurlu G, van der Laan JS, van Lijnschoten GI, Moll FCP, Ooms AHAG, van der Valk H, Tijssen JG, Bergman JJ, Meijer SL. van der Wel MJ, et al. Among authors: tijssen jg. Histopathology. 2018 May;72(6):1015-1023. doi: 10.1111/his.13462. Epub 2018 Feb 28. Histopathology. 2018. PMID: 29314176
Endoscopic duodenal mucosal resurfacing for the treatment of type 2 diabetes mellitus: one year results from the first international, open-label, prospective, multicentre study.
van Baar ACG, Holleman F, Crenier L, Haidry R, Magee C, Hopkins D, Rodriguez Grunert L, Galvao Neto M, Vignolo P, Hayee B, Mertens A, Bisschops R, Tijssen J, Nieuwdorp M, Guidone C, Costamagna G, Devière J, Bergman JJGHM. van Baar ACG, et al. Gut. 2020 Feb;69(2):295-303. doi: 10.1136/gutjnl-2019-318349. Epub 2019 Jul 22. Gut. 2020. PMID: 31331994 Free PMC article. Clinical Trial.
Performance of gastrointestinal pathologists within a national digital review panel for Barrett's oesophagus in the Netherlands: results of 80 prospective biopsy reviews.
Klaver E, van der Wel M, Duits L, Pouw R, Seldenrijk K, Offerhaus J, Visser M, Ten Kate F, Biermann K, Brosens L, Doukas M, Huysentruyt C, Karrenbeld A, Kats-Ugurlu G, van der Laan J, van Lijnschoten I, Moll F, Ooms A, Tijssen J, Meijer S, Bergman J. Klaver E, et al. J Clin Pathol. 2021 Jan;74(1):48-52. doi: 10.1136/jclinpath-2020-206511. Epub 2020 May 28. J Clin Pathol. 2021. PMID: 32467320 Free PMC article.
Duodenal mucosal resurfacing combined with glucagon-like peptide-1 receptor agonism to discontinue insulin in type 2 diabetes: a feasibility study.
van Baar ACG, Meiring S, Smeele P, Vriend T, Holleman F, Barlag M, Mostafavi N, Tijssen JGP, Soeters MR, Nieuwdorp M, Bergman JJGHM. van Baar ACG, et al. Gastrointest Endosc. 2021 Jul;94(1):111-120.e3. doi: 10.1016/j.gie.2020.12.021. Epub 2020 Dec 24. Gastrointest Endosc. 2021. PMID: 33359437 Free article. Clinical Trial.
728 results